Who Paid My Doc Search
Menu
Organisation paid for research Program year 2021 Source: CMS Open Payments

Wake Research Associates, LLC

Neither a doctor nor a teaching hospital

Research payments

$72,059

36 payments

Through program year 2021, Wake Research Associates, LLC is reported as receiving $72,059 in research payments, across 36 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $7,767 2
2020 Research $24,921 3
2019 Research $39,371 31

Breakdown

Who paid Research payments · program years 2019–2021
  1. Novo Nordisk AS $25,638 16 payments
  2. Merck Sharp & Dohme Corporation $25,006 10 payments
  3. Teva Pharmaceuticals USA, Inc. $12,734 7 payments
  4. Vanda Pharmaceuticals Inc. $8,681 3 payments
Studies the money was for Research payments · program years 2019–2021
  1. Nn9536-4376 $25,638 16 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. $11,438 2 payments
  3. Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis $8,681 3 payments
  4. A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) $7,153 3 payments
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough PN030 $6,783 1 payment
  6. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments $5,581 4 payments
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 $5,369 3 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU DAY. $984 1 payment
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 $246 2 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. $186 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record